Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lebre

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Pharmacological Research|August 27, 2021
ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinibYaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
British Journal of Pharmacology|February 23, 2020
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulationYaogeng Wang, Rolf W Sparidans, Wenlong Li, et al.
International Journal of Cancer|May 11, 2018
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinibWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)Yaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
International Journal of Pharmaceutics|November 24, 2019
P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554)Wenlong Li, Rolf Sparidans, Mujtaba El-Lari, et al.
International Journal of Pharmaceutics|April 3, 2020
Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in miceJing Wang, Maaike A C Bruin, Changpei Gan, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2021
Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinibYaogeng Wang, Rolf W Sparidans, Jing Wang, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral ExposureJing Wang, M Merve Susam, Changpei Gan, et al.
Plos One|March 6, 2013
Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammationMarieke M J Herenius, Ana S F Oliveira, Carla A Wijbrandts, et al.
Annals of the Rheumatic Diseases|September 26, 2013
Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritisM I P Ramos, O N Karpus, P Broekstra, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Pharmacological Research|August 27, 2021
ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinibYaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
British Journal of Pharmacology|February 23, 2020
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulationYaogeng Wang, Rolf W Sparidans, Wenlong Li, et al.
International Journal of Cancer|May 11, 2018
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinibWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)Yaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
International Journal of Pharmaceutics|November 24, 2019
P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554)Wenlong Li, Rolf Sparidans, Mujtaba El-Lari, et al.
International Journal of Pharmaceutics|April 3, 2020
Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in miceJing Wang, Maaike A C Bruin, Changpei Gan, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2021
Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinibYaogeng Wang, Rolf W Sparidans, Jing Wang, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral ExposureJing Wang, M Merve Susam, Changpei Gan, et al.
Plos One|March 6, 2013
Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammationMarieke M J Herenius, Ana S F Oliveira, Carla A Wijbrandts, et al.
Annals of the Rheumatic Diseases|September 26, 2013
Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritisM I P Ramos, O N Karpus, P Broekstra, et al.
Pageof 6